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Objectives:With carotid artery stenting (CAS) becoming an ever-increasing procedure, we sought to determine risk factors
for in-stent restenosis after CAS.
Methods: Consecutive patients undergoing CAS between January 2002 and October 2004 at a tertiary care hospital were
retrospectively reviewed. Patient, filter, and stent selection were left to the discretion of the attending surgeon. High-risk
patients were defined by significant comorbidities or a hostile neck (prior surgery or radiation, or both), and risk factor
analysis was performed. In-stent restenosis was defined as >60%, and selective angiography was performed on patients
with an in-stent restenosis >80% by duplex ultrasound imaging.
Results: Reviewed were 101 patients (55 men, 46 women) who underwent 109 CAS procedures. Comorbidities were
typical for patients with atherosclerosis. In addition, 38% (n  41) of procedures were performed in patients who had
prior neck surgery, of which 29% (n 32) had previous ipsilateral carotid endarterectomy. Seventeen patients (16%) had
a history of neck cancer, and all had prior neck radiation. Median follow-up was 5 months (range, 0 to 30 months).
Neurologic complications included three transient ischemic attacks (2.8%) and one nondisabling stroke (0.9%). There
were two myocardial infarctions (1.9%) and no periprocedural deaths (30 days), for a combined stroke, myocardial
infarction, and death rate of 2.9%. Asymptomatic in-stent restenosis developed in 12 carotids (11%), five of which
required endovascular intervention, with a mean of 6 months to restenosis. Univariate Cox proportional hazard
regression models were used to determine risk factors for the development of restenosis. Prior stroke, transient ischemic
attack, amaurosis fugax, and prior neck cancer were all significant risk factors. When these significant risk factors from
univariate analysis were put into multivariate analysis, however, the only marginally significant risk factor was prior neck
cancer (P  .06). Kaplan-Meier analysis revealed a cumulative freedom from in-stent restenosis at 24 months of 88% 
6% in patients without neck cancer compared with 27%  17% (P  .02) in patients with neck cancer.
Conclusions:CAS has been shown to be safe and effective in high-risk patients, with minimal adverse events. ( J Vasc Surg
2006;44:1010-5.)Carotid endarterectomy (CEA) is the treatment of
choice for patients with symptomatic carotid artery steno-
sis1 and selected patients with asymptomatic stenosis.2 The
reported perioperative risk of stroke or death in multicenter
studies is 3% to 7.5%.3-5 The operation is exceedingly
durable, with nearly 95% of patients being free from either
neurologic events or death3-5 and 80% to 90% of patients
free from restenosis during the first 5 years.6-11
With the inception of carotid artery angioplasty and stent-
ing (CAS) with embolic protection devices (EPD), a shift has
taken place in the treatment in those patients deemed to be at
high risk. High-risk patients include those with clinically sig-
nificant cardiac disease, severe pulmonary disease, contralat-
eral carotid occlusion, contralateral laryngeal-nerve palsy, re-
current stenosis after endarterectomy, and previous radical
neck surgery or radiation to the neck.3 Recently, CAS with
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1010embolic protection in high-risk patients with severe carotid
artery stenosis has been shown to be at least equivalent to
CEA with respect to stroke, myocardial infarction (MI), or
death.3 The primary end points of combined death, stroke,
or MI 30 days were lower in those patients undergoing
protected CAS (4.8%) compared with those who under-
went CEA (9.8%). The Carotid Revascularization using
Endarterectomy or Stenting Systems (CARESS) trial dem-
onstrated no significant difference of combined stroke and
death rate at 30 days (3.6% CEA vs 2.1% CAS) or at 1 year
(13.6% CEA vs 10.0% CAS). Similarly, no significant dif-
ferences were found in the combined end point of death,
stroke, or MI at 30 days (4.4% CEA vs 2.1% CAS) or at 1
year (14.3% CEA vs 10.9% CAS).5
Because CAS use is increasing, it is important to define
its durability and to identify those patients that may be at
risk for recurrent stenosis. Reports of carotid in-stent reste-
nosis are 1% to 75%12-19; however, the earlier studies with
higher restenosis rates looked at very few patients and
incorporated angioplasty alone. Subsequent studies paid
little attention to the risk factors for recurrent stenosis in
patients who had undergone CAS.
Numerous studies have shown that the presence of
restenosis is frequently asymptomatic and does not neces-
sarily require intervention.12,18 For this reason, it would be
beneficial to identify those patients who are at increased risk
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that long-term patency is maintained. In addition, several
reports have questioned the validity of duplex ultrasonog-
raphy for detecting in-stent restenosis after CAS, citing a
change in the biomechanical properties of the artery lead-
ing to a potential error in interpretation.20,21 The purpose
of this study was to identify risk factors in already high-risk
patients that would predict an increased risk for in-stent
restenosis.
METHODS
All patients undergoing CAS between the years 2002
and 2004 were retrospectively reviewed. Patient demo-
graphics, clinical presentation, radiology records, operative
notes, and clinical outcomes were obtained and available
for review in all cases. Symptomatic disease was diagnosed if
the patient experienced a transient ischemic attack (TIA) or
stroke referable to the carotid lesion. All comorbidities
were documented from history and physical examination.
Diagnosis of carotid artery stenosis was made by duplex
ultrasound imaging, computed tomographic (CT) angio-
gram, or magnetic resonance angiogram (MRA) with con-
firmation using angiogram.
Inclusion criteria for CAS were two or more coronary
vessels with 70% stenosis, an ejection fraction 30%, a
New York Heart Association functional class of III or
higher, bronchopulmonary obstructive disease, recurrent
stenosis after a previous CEA, previous radical neck surgery
or radiation therapy, surgically inaccessible lesions, and
contralateral occlusion of the ICA. All patients were given
aspirin and clopidogrel in the perioperative period.
All complications occurring30 days of the CAS were
considered perioperative morbidities. Stroke was defined as
any localized neurologic deficit lasting 24 hours and
confirmed by magnetic resonance imaging or head CT
scan. A TIA was defined as a neurologic deficit lasting
24 hours. MI was defined by the vascular attending as
documented electrocardiographic changes with concor-
dant serum elevation of creatine kinase and troponin.
All procedures were performed by vascular surgeons in
the general operating room suites using an OEC 9800
system (GE OEC Medical Systems, Salt Lake City, Utah)
and later on a Sieman Axiom Artis VBIID system (Berlin
and München, Germany).
Survival, neurologic events, and restenosis rates are
presented as defined by the Society of Vascular Surgery/
International Society for Cardiovascular Surgery Ad hoc
Committee’s recommended standards for carotid endarter-
ectomy.22 Recurrent carotid artery stenosis is defined as the
reappearance of a stenosis with a diameter reduction of
60% in the stented internal carotid artery as determined
by a duplex scan. Lesions believed to be 80% were con-
firmed by angiogram results.
Patients were kept in the hospital overnight. Carotid
duplex scans were obtained at 1, 6, and 12 months and
yearly thereafter. All duplex scans were performed by reg-
istered vascular technicians in an approved vascular labora-
tory accredited by the Intersociety Commission on Accred-itation of Vascular Laboratories. Velocity criteria were defined
as 50% to 60% stenosis (peak systolic velocity [PSV], 125 to
170 cm/s); 60% to 69% (PSV, 170 to 210 cm/s); 70% to 79%
(PSV,210 cm/s); 80% to 99% (end-diastolic velocity,145
cm/s). Criteria were not altered to account for intra-arterial
stents.
Statistical analysis. Time to restenosis was analyzed
using survival analysis methods. Survival curves were esti-
mated by the Kaplan-Meier method (SPSS Inc, Chicago,
Ill). Univariate and multivariate Cox proportional hazard
regression models were used to determine risk factors for
the development of restenosis. Because some patients un-
derwent bilateral procedures, a marginal risk set model23
was used to account for within-patient correlation.
Risk factors investigated included procedure side, gen-
der, smoking, coronary artery disease, prior coronary artery
bypass grafting (CABG), previous MI, congestive heart
failure (CHF), hypertension, hypercholesterolemia, chronic
obstructive pulmonary disease (COPD), prior stroke, TIA,
amaurosis fugax, prior ipsilateral CEA, prior neck radiation,
and prior neck cancer. For each risk factor, the hazard ratio
and associated 95% confidence interval from univariate
analysis was reported. Multivariate analysis was conducted
for those risk factors with significant P values (.05) from
univariate analysis. All analyses were conducted in Stata 9.0
(StataCorp, College Station, Texas).
RESULTS
Patient characteristics. A total of 101 patients (55
men, 46 women) underwent 109 CAS procedures. Comor-
bidities were typical for patients with atherosclerosis (Table I).
Neurologic symptoms referable to the lesion that was ulti-
mately stented were present in 40% (n  43), including
stroke, 22% (n  24); TIA, 21% (n  23); or amaurosis
Table I. Demographics of 101 patients undergoing 109
carotid angioplasty and stenting procedures
Variable* Patients, n (%)
Age 70  9 (44-90)
Male gender 55 (55)
Hypertension 80 (79)
Smoking 41 (41)
Coronary artery disease 66 (61)
Previous MI 24 (22)
Diabetes 32 (32)
Prior CABG 15 (14)
Congestive cardiomyopathy 20 (20)
COPD 17 (16)
Chronic renal insufficiency 12 (12)
Prior ipsilateral CEA 32 (29)
Prior neck Radiation 13 (13)
Stroke 24 (22)
TIA 23 (21)
Amaurosis fugax 7 (6)
CABG,Coronary artery bypass grafting;COPD, chronic obstructive pulmo-
nary disease; MI, myocardial infarction; TIA, transient ischemic attack.
*Data are presented as mean  SEM (range) or number of patients (% of
total).fugax, 6 % (n 7). Forty-eight percent (n 52) of carotids
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of previously stented carotids had an ipsilateral CEA, and
16% (n  17) of procedures were in patients with a head
and neck cancer (n 14) or lymphoma (n 3) in the neck.
Clinical outcomes. Distal EPDs were used in 84%
(n 92) of the cases. The EPD and stent systems included
the Percusurge (Medtronic, Redmond, Wash) in 7 (6.4%),
the Accunet/Acculink (Guidant, Indianapolis, Ind) in 47
(43%), and the Filter Wire andWallstent (Boston Scientific,
Marlborough, Mass) in 35 (32%). The technical success
rate was 100%.
Neurologic complications included three TIAs (2.8%)
and one nondisabling stroke (0.9%). There were two MIs
(1.9%) and no periprocedural deaths (30 days) for a com-
bined stroke, MI, and death rate of 2.9%.
Follow-up and case report. Median follow-up was
5 months (mean, 7 months; range, 0.1 to 30 months).
Asymptomatic 60% in-stent restenosis developed in 12 ca-
rotids (11%) at a median time to detection of 7 months. Five
carotids (4.6%) developed asymptomatic80% in-stent reste-
nosis by duplex imaging and required endovascular interven-
tion with a median of 7 months (range, 1 to 9 months) to
detection restenosis. No patient had neurologic symptoms.
Table II summarizes the clinical outcomes in the patients who
required reintervention for in-stent restenosis. The seven
(6.4%) carotids that went on to develop an asymptomatic
60% stenosis are being monitored with serial duplex exam-
inations.
Risk factor analysis. Univariate Cox proportional
hazard model with “within-patient correlation” corrected
using marginal risk set method indicated that prior stroke,
TIA, amaurosis fugax, and prior neck cancer were signifi-
cant risk factors (Table III); however, when these signifi-
cant risk factors from univariate analysis were put into
multivariate analysis, none were significant. The only mar-
ginally significant risk factor was prior neck cancer (P 
.06). The results indicate that prior neck cancer could be a
risk factor for restenosis. Kaplan-Meier analysis revealed a
cumulative freedom from in-stent restenosis of 88%  6%
in patients without neck cancer compared with 27% 17%
Table II. Clinical outcomes in five patients requiring
reintervention for in-stent restenosis*
Patient
no. Initial indication
Time to restenosis
detection Treatment
1 Neck cancer (radiation,
radical dissection)
7 months PTA
2 Neck cancer (radiation,
radical dissection)
1 month PTA/stent
3 Previous CEA 7 months PTA
4 Previous CEA 9 months PTA
5 Neck cancer (previous
radiation)
6 months None
CEA, Carotid endarterectomy; PTA, percutaneous transluminal angio-
plasty.
*None of the five patients had symptoms of restenosis.(P  .02) in patients with neck cancer. Fig 1 shows theKaplan-Meier estimated survival curves for patients with
and without prior neck cancers.
DISCUSSION
The development of improved endovascular technol-
ogy, specifically EPDs, has advanced the treatment of ca-
rotid stenosis by CAS in high-risk patients. In fact, indica-
tions for CAS are expanding with the demonstration of
excellent results. As we gain greater experience with endo-
Table III. Risk factors in patients for developing
60% restenosis
Variable HR 95% CI P*
Prior CABG N/A† N/A† N/A†
Hypertension N/A† N/A† N/A†
COPD 0.48 0.05, 4.88 0.53
Coronary artery disease 0.50 0.14, 1.82 0.29
Gender 0.57 0.14, 2.35 0.44
Previous MI 0.63 0.13, 3.15 0.58
Hypercholesterolemia 0.84 0.21, 3.37 0.80
Procedure side 0.87 0.32, 2.33 0.78
CHF 0.88 0.10, 7.88 0.91
Smoking 0.91 0.24, 3.53 0.89
Prior ipsilateral CEA 0.97 0.26, 3.65 0.96
TIA 2.91 1.02, 8.31 0.047
Prior neck radiation 3.59 0.97, 13.3 0.06
Prior neck cancer 4.01 1.08, 14.9 0.04
Stroke 8.75 1.01, 75.8 0.049
Amaurosis fugax 9.76 1.74, 50.8 0.01
HR, Hazard ratio; CI, confidence interval; CABG, coronary artery bypass
graft;COPD, chronic obstructive pulmonary disease;MI,myocardial infarc-
tion; CHF, congestive heart failure; CEA, carotid endarterectomy; TIA,
transient ischemic attack.
*Univariate Cox proportional hazard model with marginal risk set method
to correct within-patient correlation was used to determine the significance.
†The hazard ratio was not estimable since all the restenosis occurred in
patients without CABG or patients with hypertension.
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Fig 1. Kaplan-Meier analysis showing the cumulative freedom
from ISR in patients who had neck cancer compared to those
patients who did not. The solid line represents the cumulative
freedom from restenosis in patients without neck cancer. The
lower dashed line is the curve for patients with Neck Cancer who
had a standard error 10%.vascular techniques, however, it is essential to correctly
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vances in medical management, those patients deemed to
be high risk are living longer and therefore should be
offered treatment with proven durability. With this in
mind, we reviewed the results of a single institution’s
experience in an attempt to determine predictors of reste-
nosis.
CAS with an EPD has been shown to be equivalent to
CEA in high-risk patients.3 Accordingly, high-risk patients
were reviewed retrospectively to determine if any risk fac-
tors were associated with recurrent carotid artery stenosis.
Univariate analysis identified prior stroke, TIA, amaurosis
fugax, and neck cancer as significant risk factors for reste-
nosis. When these factors were analyzed by multivariate
analysis, a history of head and neck cancer was found to be
a marginally significant risk factor for the development of
early in-stent restenosis. This was confirmed by Kaplan-
Meier survival curves comparing freedom from in-stent
restenosis in patients with prior neck cancer with those
without.
The incidence of recurrent stenosis in CEA has been well
studied. Published restenosis rates after CEA are 2.7% to
19%.24-29 Earlier studies tended to have higher restenosis rates
because more primary closures were being performed. Ouriel
and Green30 noticed the increased rate of restenosis in women
and in arteries that were closed primarily.30 AbuRahma et al31
showed the utility of patch closure in the prevention recurrent
stenosis. To date, however, far fewer studies have looked at
recurrent stenosis after CAS, which is at least partly due to the
more recent development of CAS. In this study, the overall
incidence of 60% restenosis was 12%, and the overall inci-
dence of restenosis that required reintervention was 4.6%,
which is similar to the 2.4% to 14% found by other
investigators.12,13,17-19,32,33 A review of the global carotid
registry, which included 12,392 procedures, found the reste-
nosis rate after CAS to be 2.7%, 2.6%, and 2.4% at 1, 2, and 3
years, respectively.33 Thus, the results presented in this study
and in the previously mentioned studies are favorable com-
pared with restenosis rates after CEA.
As CAS becomes more prevalent and is applied more
broadly to patients with carotid disease, it is imperative to
continue to review risk factors to best determine who is at
risk for recurrence because durability of the procedure will
come into question. Recent studies suggest that previous
CEA is a risk factor for restenosis. Zhou et al34 reviewed
208 CAS procedures in 188 patients and found a 3.4%
incidence of in-stent restenosis. Risk factor analysis identi-
fied patients with previous CEA to be at risk for in-stent
restenosis.
Although previous CEA was not a risk factor for in-
stent restenosis in this current study, it highlights the point
that these patients need to be monitored closely. Risk
factors that were previously associated with recurrent ca-
rotid stenosis after CEA include small carotid arteries,
female sex, and primary closure.30 Although size of the
vessel was not studied and primary closure was not a tech-
nical issue, we found no difference between men and
women with respect to restenosis. Furthermore, the risk ofrestenosis was not associated with prior stroke, TIA, hyper-
tension, smoking, coronary artery disease, previous MI,
prior CABG, CHF, COPD, chronic renal insufficiency,
device used, or prior ipsilateral CEA.
The current study found that patients with a history
of head and neck cancer or a cancer in the neck were at a
marginally significantly increased risk for development of
early in-stent restenosis after CAS. The freedom from
restenosis was significantly lower in patients with prior
neck cancer. Interpretation may be difficult, however,
because no standardized duplex criteria for patients with
carotid stents exist. In addition, the total number of
patients with in-stent restenosis was low. Regardless, it
seems to warrant a vigilant follow-up in patients with
neck cancer.
Despite the time to restenosis occurring in the typical
time frame for a neointimal hyperplastic response, these
lesions did not go on to become symptomatic. A combina-
tion of factors may influence in-stent restenosis, including
radiation therapy and previous neck surgery. Although
both ionizing radiation and prior neck surgery were not
significant risk factors for restenosis on their own, prior
neck cancer serves as a marker that stratifies patients into
treatment modalities that may be enough to incite in-stent
restenosis. The exact dose of radiation was not determined,
but current regimens for malignant lymphomas and head
and neck cancers include high-dose radiation to the tumor
bed. Unfortunately, the carotid arteries are frequently in
the field of treatment.
Radiation-associated vascular injury has been investi-
gated and shown to cause damage consistent with athero-
sclerosis. Intimal proliferation, selective disruption of the
internal elastic lamina, and necrosis has been noted in both
small and large vessels.35-37 The mechanism of carotid
artery stenosis secondary to radiotherapy is believed to be a
combination of direct vessel wall damage, leading to inti-
mal proliferation, necrosis of the media, periadventitial
fibrosis, and accelerated atherosclerosis. In addition, the
indirect effect of radiation-induced obliteration of the ad-
ventitial vasa vasorum may contribute.38,39 Little data cur-
rently exist on the mechanism of in-stent restenosis; how-
ever, local changes in flow dynamics and vascular wall
damage are prime suspects. In addition to these effects,
radiation may further exacerbate vessel wall damage and
changes in the local hemodynamics, increasing the rate of
in-stent restenosis after CAS. Furthermore, the effect of
radiation may be long-term, predisposing to progressive
restenosis.
Diagnosis of recurrent stenosis after CAS remains prob-
lematic, and in the case of this study, one patient with a
presumed 80% to 99% stenosis underwent an angiogram
that found 60% stenosis. Stringent follow-up is imperative
to determine which patients have hemodynamically signif-
icant lesions. Duplex ultrasonography is noninvasive, safe,
free of complications, and readily available.
Some authors have raised concerns of the utility of
current velocity criteria and the need to refine the criteria
for patients with carotid stents.40,41 A study by Lal et al20
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changes the biomechanical properties of the artery, ulti-
mately affecting the velocity and therefore the diameter and
mimicking an in-stent restenosis. The stent ultimately de-
creases the compliance of the vessel, leading to falsely
elevated velocities. Willfort-Ehringer et al42 discuss positive
remodeling forces of the stent placement and negative
arterial remodeling of neointimal proliferation. The two
forces seemed to counteract each other. The presence of
the radiation is certainly a factor that affects the arterial wall.
The hyperplasia may certainly be enough to overcome any
positive remodeling from stent placement, thus increasing
the likelihood of restenosis.
To date, there are no standardized criteria for the
detection of restenosis in previously stented carotids. For
this reason, our laboratory used duplex ultrasonography for
screening. All hemodynamically significant stenosis were
confirmed by arteriography. The focus of this study was not
to define a new set of criteria for restenosis in patients with
previous carotid stent.
Upon reintervention, all patients with 80% in-stent
restenosis had an endovascular approach to treatment. Al-
though balloon angioplasty was used in all cases, stent
placement was performed in selected cases. The optimal
management of in-stent restenosis has yet to be deter-
mined. Zhou et al17 and Levy et al34 were proponents of
angioplasty or cutting balloons, whereas others have used
open conversion.43 The exact etiology of in-stent restenosis
is unclear in this patient population, and the ideal treatment
approach to halt the process has yet to be determined. The
patients in this study were only treated with angioplasty and
selective stenting. Continued follow-up will determine if
this is a viable treatment approach.
Although exact rates of restenosis after CEA in radi-
ated necks are unclear, certainly perioperative risk factors
are increased, especially that of nerve injury.44 In addi-
tion, surgery is difficult because of arterial, periarterial,
and cutaneous sclerosis and risk of infection.45 In con-
trast, CAS offers an approach that circumvents any dissec-
tion in these difficult fields. In addition, this procedure
can be performed with minimal risk of stroke, death, or
MI. Thus, although CAS in patients with prior neck
cancer had a higher rate of in-stent restenosis compared
with patients without prior neck cancer, it is still the
intervention of choice in this patient population. Only a
direct comparison of CEA vs CAS in radiated necks
would answer the question of which is the procedure of
choice. Although the study is limited by the short fol-
low-up period and only a moderately sized population,
which could lead to a type II error, it confirmed the
safety and efficacy of CAS and identified patients with an
increased risk of in-stent restenosis. In addition, given
the low number of events, the study is limited by the
number of factors adjusted. This precluded a more ex-
tensive multivariable model, and some risk factors may
have been excluded.CONCLUSION
It is clear that CAS with EPD is a safe procedure that
may be performed with a low incidence of stroke, TIA, MI,
or death. Further, CAS may be performed with a low
incidence of recurrent stenosis. In fact, CAS may be the
intervention of choice under certain circumstances such as a
hostile neck. Although patients who have had previous
neck cancer are at slightly increased risk for restenosis, no
neurologic events developed in patients with in-stent reste-
nosis in this study. Thus, CAS should still be the procedure
of choice in this patient population. This study would
suggest, however, that this patient population may need to
be monitored more closely.
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